Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benjamin Morgan Scirica, M.D.

Co-Author

This page shows the publications co-authored by Benjamin Scirica and Christopher Cannon.
Connection Strength

3.776
  1. Treatment of elevated cholesterol. Circulation. 2005 May 31; 111(21):e360-3.
    View in: PubMed
    Score: 0.318
  2. Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program. Am Heart J. 2021 Sep 03; 243:15-27.
    View in: PubMed
    Score: 0.246
  3. Digital Care Transformation: Interim Report From the First 5000 Patients Enrolled in a Remote Algorithm-Based Cardiovascular Risk Management Program to Improve Lipid and Hypertension Control. Circulation. 2021 Feb 02; 143(5):507-509.
    View in: PubMed
    Score: 0.232
  4. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. Am Heart J. 1999 Dec; 138(6 Pt 1):1065-72.
    View in: PubMed
    Score: 0.217
  5. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. 1999 Nov 15; 84(10):1145-50.
    View in: PubMed
    Score: 0.217
  6. Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. Am Heart J. 2018 08; 202:54-60.
    View in: PubMed
    Score: 0.195
  7. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Arrhythm Electrophysiol. 2016 Feb; 9(2):e002951.
    View in: PubMed
    Score: 0.167
  8. Clinical implications and correlates of Q waves in patients with ST-elevation myocardial infarction treated with fibrinolysis: observations from the CLARITY-TIMI 28 trial. Clin Cardiol. 2014 Mar; 37(3):160-6.
    View in: PubMed
    Score: 0.145
  9. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10; 57(19):1908-16.
    View in: PubMed
    Score: 0.120
  10. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010 Aug; 31(16):1993-2005.
    View in: PubMed
    Score: 0.113
  11. Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction. Am Heart J. 2010 Jan; 159(1):55-62.
    View in: PubMed
    Score: 0.109
  12. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009 Feb; 55(2):265-73.
    View in: PubMed
    Score: 0.102
  13. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 06; 50(19):1844-51.
    View in: PubMed
    Score: 0.094
  14. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007 Oct; 53(10):1800-7.
    View in: PubMed
    Score: 0.093
  15. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis. 2006 Oct; 22(2):95-102.
    View in: PubMed
    Score: 0.087
  16. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol. 2006 Jul 04; 48(1):37-42.
    View in: PubMed
    Score: 0.085
  17. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006 Jun 06; 47(11):2326-31.
    View in: PubMed
    Score: 0.085
  18. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation. 2005 Mar 15; 111(10):1217-24.
    View in: PubMed
    Score: 0.078
  19. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol. 2002 Oct 15; 90(8):821-6.
    View in: PubMed
    Score: 0.066
  20. Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. Crit Pathw Cardiol. 2002 Sep; 1(3):150-8.
    View in: PubMed
    Score: 0.066
  21. Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002 Aug 01; 90(3):303-5.
    View in: PubMed
    Score: 0.065
  22. Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. Circulation. 2021 Feb 16; 143(7):685-695.
    View in: PubMed
    Score: 0.059
  23. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021 01 14; 384(2):129-139.
    View in: PubMed
    Score: 0.058
  24. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation. 2021 Feb 02; 143(5):470-478.
    View in: PubMed
    Score: 0.058
  25. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. Am J Cardiol. 2020 05 15; 125(10):1577-1581.
    View in: PubMed
    Score: 0.055
  26. Extending i2b2 into a framework for semantic abstraction of EHR to facilitate rapid development and portability of Health IT applications. AMIA Jt Summits Transl Sci Proc. 2019; 2019:370-378.
    View in: PubMed
    Score: 0.052
  27. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. J Am Coll Cardiol. 2019 04 02; 73(12):1596-1598.
    View in: PubMed
    Score: 0.052
  28. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019 03 12; 139(11):1384-1395.
    View in: PubMed
    Score: 0.052
  29. Emergency department thrombolysis critical pathway reduces door-to-drug times in acute myocardial infarction. Clin Cardiol. 1999 Jan; 22(1):17-20.
    View in: PubMed
    Score: 0.051
  30. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. J Am Coll Cardiol. 2018 12 25; 72(25):3370-3372.
    View in: PubMed
    Score: 0.051
  31. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease. J Am Coll Cardiol. 2016 07 19; 68(3):322-323.
    View in: PubMed
    Score: 0.043
  32. Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. Heart. 2014 Nov; 100(22):1762-9.
    View in: PubMed
    Score: 0.037
  33. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clin Cardiol. 2013 Mar; 36(3):139-45.
    View in: PubMed
    Score: 0.034
  34. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2012 Oct 23; 60(17):1623-30.
    View in: PubMed
    Score: 0.033
  35. Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). Am J Cardiol. 2011 May 15; 107(10):1441-6.
    View in: PubMed
    Score: 0.030
  36. Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J. 2011 Jun; 32(11):1390-7.
    View in: PubMed
    Score: 0.030
  37. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 08; 57(6):672-84.
    View in: PubMed
    Score: 0.029
  38. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). JACC Cardiovasc Interv. 2010 Nov; 3(11):1166-77.
    View in: PubMed
    Score: 0.029
  39. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010 Nov 11; 363(20):1909-17.
    View in: PubMed
    Score: 0.029
  40. Early dynamic risk stratification with baseline troponin levels and 90-minute ST-segment resolution to predict 30-day cardiovascular mortality in ST-segment elevation myocardial infarction: analysis from CLopidogrel as Adjunctive ReperfusIon TherapY (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28. Am Heart J. 2010 Jun; 159(6):964-971.e1.
    View in: PubMed
    Score: 0.028
  41. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57.
    View in: PubMed
    Score: 0.027
  42. Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology. Am J Cardiol. 2009 Feb 01; 103(3):307-11.
    View in: PubMed
    Score: 0.025
  43. Delay in thrombolysis administration: causes of extended door-to-drug times and the asymptote effect. J Emerg Med. 1998 Jul-Aug; 16(4):557-65.
    View in: PubMed
    Score: 0.012
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.